Long-term study of KarXT and KarX-EC for agitation in Alzheimer's disease
Tests KarXT and KarX-EC over time in people with Alzheimer's-related agitation.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Deagu, Incheon, and Seoul, South KoreaSee the 10 sitesAlso in 25 other countries, 231 sites
- Trial code
- NCT06937229
- EU 2024-519994-20-00
- U1111-1316-3903
- Registry title
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 650 people, planned
- Started
- 2 Dec 2025
- Expected to end
- 20 Jul 2029
- Type of study
- Interventional
- Treatments tested
- KarXT
- KarX-EC
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 55 to 90 with agitation linked to Alzheimer's disease who finished study CN012-0023 or CN012-0024 and have a caregiver.
- Age
- 55 to 90 years
- Sex
- All sexes
- Disease stage
- Agitation associated with Alzheimer's disease.
- Earlier treatment
- Must have completed study CN012-0023 or CN012-0024 as the protocol requires.
Main reasons for not taking part
- Clinically significant heart, lung, kidney, blood, gut, hormone, immune, skin, nerve or cancer disease
- Any other condition the investigator thinks could harm the person's safety or the study results
- Other exclusion rules set by the protocol
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants must have completed study CN012-0023 or CN012-0024 per protocol
- Participants must have an identified caregiver who has sufficient contact (approximately 8 hours over a week)
Who cannot take part
- Participants must not have clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results
- Other protocol-defined Inclusion/Exclusion criteria apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
- Has a doctor told you that you have Alzheimer's disease?
- Do you have agitation caused by Alzheimer's disease, such as being restless or aggressive?
- Have you taken part in an earlier study of the same medicine (KarXT or ML-007C-MA) and finished it?
- Do you have a caregiver or trial partner who sees you regularly and can help with the study?
Where in South Korea
Also in 25 other countries, 231 sites
- Deagu, Taegu-KwangyǒkshiHospital not named in the registryContact: Site 2400Not yet recruiting
- IncheonHospital not named in the registryContact: Site 2409Not yet recruiting
- Inha University HospitalIncheon, South KoreaContact: Seong Hye Choi, Site 2401Taking people
- SeoulHospital not named in the registryContact: Site 2402Not yet recruiting
- SeoulHospital not named in the registryContact: Site 2405Not yet recruiting
- Gangnam Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Hanna Cho, Site 2408Taking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Seol-Heui Han, Site 2403Taking people
- Seoul National University HospitalSeoul, South KoreaContact: Manho Kim, Site 2407Taking people
- The Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaContact: Hyun-Kook Lim, Site 2404Taking people
- Seoul, Seoul-teukbyeolsi [Seoul]Hospital not named in the registryNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
The group in the trial
- KarXT+KarX-ECTreatment being tested
Treatment: KarXT and KarX-EC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
- Plain-language title
- Long-term study of KarXT and KarX-EC for agitation in Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06937229, who can take part
- Record updated
- 12 November 2026